Truth in Health Innovation

Commercializing the latest advancements in medical device technology to address identifiable needs within the healthcare market.

We believe all women with breast cancer should have access to highly-effective, cost-efficient radiation therapy. We believe in radiation therapy that targets breast tissue while sparing vital organs such as the heart and lungs and lowering whole body dose.


MammoKnife: the world’s first self-shielded radiotherapy treatment dedicated to breast cancer

The MammoKnife is first in a line of innovative radiotherapy devices that obviate the need for additional costly shielding or bunkers. By eliminating the need for a conventional bunker costing as much as $5M, the self-shielded MammoKnife will transform the delivery of breast cancer treatment worldwide. The instrument can be placed in any treatment center or medical office and can be used in a mobile setting to bring state-of-the-art breast cancer care to both rural and low-income urban areas that remain drastically underserved.

Designed to spare surrounding healthy tissue from unwanted radiation

Our patented technology allows the practitioner to deliver whole or partial breast irradiation while minimizing exposure to critical structures at risk such as lung, heart and skin, and lowering whole body dose to the patient. By offering these advantages, clinicians can apply novel approaches such as accelerated radiation treatment to reduce procedure time as well as allowing for advanced techniques such as stereotactic radiation therapy.

MammoKnife provides the best current radiotherapy solutions in a self-shielding enclosure and qualifies for 510(k) regulatory clearance pathway

Prone positioning
Prone patient positioning isolates breast from organs at risk for superior treatment and minimal secondary dose

Integrated imaging options
These can include cone-beam CT and dedicated breast spiral CT for treatment planning

MammoKnife Prototype

360° rotation
Allows for delivery of optimized non-invasive accelerated partial breast, true intensity-modulated treatment plans, multi-target techniques, and radiosurgery of the breast while sparing healthy organs

Self-shielded structure
Can be deployed anywhere and allows for a dramatically reduced cost of ownership in addition to a significantly shorter installation timeframe

Leverages current standards
The 6-MV Linear accelerator is the standard for whole or partial breast irradiation with boost and can be used for stereotactic surgery. It is compatible with most treatment planning systems and uses existing CPT codes for reimbursement.

Qualifies for 510(k) regulatory clearance pathway
By performing the same treatments as presently marketed devices, MammoKnife is “substantially equivalent” and does NOT require clinical trials. Moreover, reimbursement codes for the therapies delivered by the machine are already in place. This greatly simplifies the path to market and removes significant risk and cost of commercialization.

Learn more about entering the $4 billion-dollar worldwide market of radiotherapy
Ehmet Health is in the process of securing the necessary capital to develop the initial units for patient use and expect both FDA and CE clearance for these units that will be in clinical operation in both North America and Europe. The proprietary technology of MammoKnife was developed with nearly 3MM dollars in federal grants in addition to reinvestment from the sale of its first of its kind contoured prone breast board trademarked the ClearVue.

Breast cancer remains the leading cancer in women, yet radiation equipment and techniques for breast cancer have barely changed in the last decades. We believe in transforming breast cancer care by improving access to state-of-the-art radiotherapy so women can receive the advanced techniques already improving outcomes in other types of cancer.


EhmetProton, the KodaOne system... information coming soon.

Our commitment to excellence extends throughout our service engineering family. Our members on average maintain a decade of experience installing and maintaining medical devices for some of the World’s most recognized institutions.

Our Facility

Located in Plymouth, MI, seated alongside our manufacturing partners’ 50,000 sqft advanced design and assembly space.

The FDA registered facility has been manufacturing and delivering devices to the Fortune 500 community for over fifteen years. The location was carefully chosen to allow Ehmet Health the ability to drive prototypes efficiently through the design stage allowing rapid adaptation to market needs.

Our Team

Ehmet Health is made up of skilled individuals derived from a wide spectrum of areas within health care. Each sharing one common vision, to bring a distinguished honesty to the medical device industry. Our team has a long history of involvement in the commercialization of medical devices with special focus in medical imaging and particle beam therapy. The high level of experience of our consortium of professionals leverages a wisdom that is beyond compare and unrivaled in the marketplace.

Management Team

Michael Teicher, Chief Executive Officer, brings over 20 years of experience in operations, financing and advising senior executives of medical companies on strategy, operations, and capital market exposure. He most recently led the turnaround of one the largest point of care CT companies. With the previous proposed exit, Michael and his team were contracted by one of the nation’s leading oncology providers and became integral members of the team that led the completion of a complex proton system in addition to developing an innovative integrated CBCT imaging system that received FDA 510(k) clearance for use at that center.

Neal Clinthorne, Chief Technology Officer, is a world-renowned Research Professor Emeritus in Radiology from the University of Michigan. He has written nearly 100 peer-reviewed articles, has been granted over 20 patents, and has extensive experience in technology commercialization.

Alan Sliski, Chief Scientific Officer, is a prolific entrepreneur and scientist with a specialty in radiation therapy systems. He has founded several companies, written numerous highly regarded publications, and most notably founded photo Electron (now Zeiss), as well as Mevion Medical Systems, and currently holds 24 patents.

Leonard A. Farber MD, Chief Medical Officer, brings over 20+ years of clinical and entrepreneurial expertise in Radiation Oncology in both private practice and in academia, with concentrated focus on emerging technologies in breast cancer.

Kevin Murphy MBA, Chief Financial Officer, is a seasoned healthcare executive and has completed over $100 billion dollars in M&A has over 20 years on Wall Street in finance and operational administration in both the public and private sector. Kevin graduated from MIT and holds an MBA from Columbia.

Julia E. Williams, Global Executive Advisor & Director of Patient Advocacy, currently serves as a Regional Business Development Manager for Clinical Laboratory & Anatomic Pathology within Academic Medicine & Community Healthcare. She is also a Managing Partner of JW Oncology Network, an executive retained firm dedicated to the advancement of Oncology & Research Medicine. Julia remains very active in cancer and research through her industry advisory roles, consulting, cancer recruitment activities, and committee engagements. Julia is a breast cancer survivor that believes in providing patients with quality care and the best options available. She is excited to be a part of the team and to work with other breast cancer survivors to develop this program for EHMEThealth.

Advisory Team

Our organization maintains a team of seasoned business advisors all whom have served in executive roles either within the fortune 100 sector or leading within their respective fields both in and outside of healthcare. Their insight has been critical as we navigate an ever-changing marketplace that will continue to evolve as we further globalize our brand. Our advisory team is led by Mr. Gregory Lane Esq.

Greg Lane, Executive Vice President and Chief Administrative Officer of McLaren Health Care Corporation. Greg is a graduate of the University of Michigan and received his Juris Doctorate from Detroit College of Law, where he served as Editor-in-Chief of the Law Review. Prior to joining McLaren, Mr. Lane was in private legal practice and specialized in corporate and health care law. Mr. Lane is the past 2018-2019 Chair of Michigan Health and Hospital Association (MHA). Mr. Lane also serves on several other Boards, and his professional affiliations include the State Bar of Michigan, the American Bar Association, the American Health Lawyers Association and the American College of Healthcare Executives.

Let's Connect

Want to know more about Ehmet Health and what’s coming on the horizon? Simply fill out the form below and we will get back with you as soon as possible with more information!



+ 1 800.459.1945



back to top